Regulated healthtech commercialization and market entry | Vahana Labs
Vahana LabsHealthcare value creation
SaMD · Medtech · Diagnostics · Digital therapeutics · Wellness products entering regulation · AI-enabled clinical products

Your product works. That does not make it commercially ready.

Healthtech companies secure authorization, complete pilots, and sign customers without reaching repeatable, profitable use. Vahana Labs finds the decisions blocking commercialization and sequences them before they become expensive commitments.

Two clinicians reviewing a treatment planning console in a radiation oncology suite
Routine use is the bar. Authorization, pilots, and go-live are not.
Nearly two decades

Inside health technology

SaMD to diagnostics

Clinical AI, digital health, connected products

FDA, NHS, VA

Work involving Gilead and Moderna programs

30+ regulated products

Brought to market across devices, SaMD, and diagnostics

Most commercialization problems are sequence problems

Managed separately, these decisions produce approvals, pilots, and integrations without commercial momentum. PACE is the order they actually run in.

The chain
Regulatory strategy sets claims
Claims set evidence
Evidence sets the buyer
The buyer sets payment and workflow
Workflow sets implementation and contracting
P

Pick the market

Choose the indication, buyer, use case, channel, and payment model that can support a viable business. A large market is not necessarily an enterable one.

Determines  what has to be built and proven
A

Align what must be true

Connect regulatory strategy, claims, evidence, reimbursement, economics, and contractual obligations. A product can be clinically valuable and authorized without being buyable.

Determines  whether interest can become an enterprise commitment
C

Convert interest into routine use

Design pilots, procurement, workflow integration, and adoption around the decision that has to follow. Many companies can secure pilots. Far fewer convert them into sustained use.

Determines  whether the product produces real-world value
E

Extend the advantage

Evidence, integrations, buyer materials, and contract positions should become reusable capabilities. When they do not, complexity grows as quickly as revenue.

Determines  whether the next market entry is easier than this one

Where should the next indication, buyer, market, or deployment be faster and less expensive than the last — and why isn’t it?

The outcome commercialization should be measured against

The goal is cleanly paid, routine, evidence-supported use

A small adhesive monitoring device worn on a person's upper arm
Cleanly paid

A viable contracting and payment model, not pilot funding.

Routine

Embedded in normal workflow, not dependent on one champion.

Evidence-supported

Claims appropriate for the product, population, and buyer.

Use

Actively influencing care, not merely authorized or available.

Milestones often celebrated instead Authorization Pilot completion Technical go-live Contract signature

Where commercialization leverage breaks

These are rarely isolated regulatory, commercial, or product failures. They occur at the seams between functions.

Symptoms
The evidence demonstrates performance but does not answer the purchasing question.
There are champions but no economic buyer, and reimbursement strategy is aimed at a code.
Pilots produce positive results but no purchasing decision.
Every customer requires a different integration, and services consume the margin.
A new indication repeats work the company believed it had completed.
What scale requires
Implementation margin. Each deployment costs less than the last.
Sales-cycle repeatability. The same evidence and contract positions work for the next buyer.
Renewal and expansion. Use is routine enough that renewal is a formality.
Referenceability. Customers can describe the economic result, not only that the product works.
Best fit
A real product in market, regulated or heading there
Preparing for US entry, a new indication, a new buyer, or production expansion
Decisions that span more than one function
A need to act within the next 30 to 90 days

Not regulatory submission writing, lead generation, coding research, or a market landscape with no decision attached.

The engagement

Commercialization Leverage Diagnostic

For SaMD, DTx, diagnostic, and AI-enabled clinical companies facing a material commercialization decision in the next 30 to 90 days.

What is blocking commercialization, and what must leadership resolve?

You leave with
The primary commercialization constraint
The assumptions most likely to fail
The decisions currently being made in the wrong sequence
The two or three decisions leadership must resolve next
Find the constraint →
If the path is viable

Commercialization Sequencing Plan

What should the company do, in what order, with which owners and evidence?

The order in which claims, evidence, payment, workflow, and implementation must be resolved
What must be proven before the next commitment of capital
Named owners across regulatory, clinical, commercial, and product
The measures that show the model is becoming repeatable

Built by an operator who has carried regulated products beyond approval

Arvita Tripati has nearly two decades across SaMD, diagnostics, clinical AI, regulatory strategy, privacy, evidence, and enterprise adoption — including FDA-regulated AI-enabled products, entry into NHS and VA environments, and scaling regulated clinical platforms involving organizations such as Gilead and Moderna.

The advantage is not another isolated functional opinion.

It is seeing how the decisions interact before they become expensive constraints.

More on the background

Start with the constraint

You do not need another generic commercialization plan. You need to know what stands between the product and cleanly paid, routine, evidence-supported use.

Pressure-test your commercialization plan →